Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia
and obvious bone marrow erythroblastic cells decreased. Cyclosporine A and /or steroids are
the first line therapy but some patients were refractory or intolerance to the treatment. The
effects of the second line therapy are also not satisfactory and sometimes not available. The
investigators aim to explore the efficacy and side-effect of sirolimus for newly diagnosed
primary acquired PRCA.